Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • In Your Element
  • Published:

Redefining peptide therapeutics with semaglutide

Thomas Kruse and Søren Østergaard reflect on the development of the GLP-1 analogue, semaglutide, which is reshaping peptide therapeutics in type 2 diabetes, weight management, and beyond.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout


  1. World Obesity Atlas 2023 (World Obesity Federation, 2023)

  2. Drucker, D. J., Habener, J. F. & Holst, J. J. J. Clin. Invest. 127, 4217–4227 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  3. Kurtzhals, P., Østergaard, S., Nishimura, E. & Kjeldsen, T. Nat. Rev. Drug Discov. 22, 59–80 (2022).

    Article  PubMed  Google Scholar 

  4. Kurtzhals, P. et al. Biochem. J. 312, 725–731 (1995).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Knudsen, L. B. et al. J. Med. Chem. 43, 1664–1669 (2000).

    Article  CAS  PubMed  Google Scholar 

  6. Lau, J. et al. J. Med. Chem. 58, 7370–7380 (2015).

    Article  CAS  PubMed  Google Scholar 

  7. Garvey, W. T. et al. Nat. Med. 28, 2083–2091 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity (SELECT) (US National Library of Medicine, 2023);

  9. Tschöp, M. H. et al. Cell Metab. 24, 51–62 (2016).

    Article  PubMed  Google Scholar 

  10. Jastreboff, A. M. et al. New Engl. J. Med. 387, 205–216 (2022).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Thomas Kruse.

Ethics declarations

Competing interests

T.K. and S.O. are employees and shareholders of Novo Nordisk.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kruse, T., Østergaard, S. Redefining peptide therapeutics with semaglutide. Nat. Chem. 16, 296 (2024).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing